Andere Sprachen Shandong Boan Biotechnology Co., Ltd.

Aktien

A3D4SN

CNE100005RV4

6955

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:39 28.05.2024			% 5 Tage	% 1. Jan.
9,8 ^HKD	0,00 %		-0,91 %	-36,77 %

06:08	China akzeptiert den Antrag von Boan Biotechnology auf eine biologische Lizenz für ein Medikament gegen Typ-2-Diabetes	MT
27.05.	Shandong Boan Biotechnology GCTB-Arzneimittel erhält Marktzulassung von NMPA	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

China Accepts Boan Biotechnology's Biologics License Application for Type 2 Diabetes Drug	06:08
Shandong Boan Biotechnology GCTB Drug NMPA's Marketing Approval	27.05.
Shandong Boan Biotechnology Co., Ltd. Enters into Loan Facility with China Jingu International Trust Co., Ltd	12.04.
Shandong Boan Biotechnology Completes Phase 3 Trial for Retina Injection	08.04.
Shandong Boan Biotechnology Co., Ltd. Completes Phase 3 Clinical Trial in China for Aflibercept Intravitreous Injection and Plans to Submit Biologics License Application	08.04.
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon	08.04.
Shandong Boan Biotechnology Trims Attributable Loss in 2023	26.03.
Shandong Boan Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	25.03.
Shandong Boan Biotech Completes Phase 3 Trial for Type 2 Diabetes Injection; Shares Surge 10%	08.03.
Shandong Boan Biotechnology Co., Ltd. Announces Phase 3 Clinical Trial Completed in China for Dulaglutide Injection	08.03.
Shandong Boan Biotechnology Authorizes CDMO Service Provider to Use Stable Cell Line Development Platform	30.01.
Shandong Boan Biotechnology Co., Ltd. Enters into Agreement with the Zencore Biologics Co., Ltd	30.01.
Boan Biotechnology, Joincare Sign Exclusive License Deal for Respiratory Disease Treatment	29.01.
Shandong Boan Biotechnology Co., Ltd. Announces Orphan Drug Designations for Treatment of Gastric Cancer by FDA	24.01.
Boan Biotechnology Secures Brazilian GMP Certification For Cancer Drug	18.01.
Shandong Boan Biotechnology Co., Ltd. Obtains GMP Certification for Boyuno®? from the Brazilian Agencia Nacional De Vigilancia Sanitaria	17.01.
Boan Biotech Completes Enrollment for International Multicenter Comparative Clinical (Phase 3) Study of Its Denosumab	12.01.
Shandong Boan Enrolls Participants for Denosumab Injection Trials in EU, US and Japan	04.01.
Certain H Shares of Shandong Boan Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 30-DEC-2023.	30.12.
Shandong Boan Biotechnology Gets Orphan Drug Designations for Pancreatic Cancer Treatment	28.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Shandong Boan Biotechnology Co., Ltd.

Aktien

A3D4SN

CNE100005RV4

6955

Andere Sprachen

Filter